This is therefore a comparing of the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership in Immunomedics Inc. (NASDAQ:IMMU) and Cytokinetics Incorporated (NASDAQ:CYTK). The two are both Biotechnology companies that compete with one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Table 1 highlights Immunomedics Inc. and Cytokinetics Incorporated’s gross revenue, earnings per share (EPS) and valuation.
Table 2 represents Immunomedics Inc. (NASDAQ:IMMU) and Cytokinetics Incorporated (NASDAQ:CYTK)’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Immunomedics Inc. has a 1.96 beta, while its volatility is 96.00%, thus making it more volatile than S&P 500. Cytokinetics Incorporated has a 1.65 beta and it is 65.00% more volatile than S&P 500.
The next table highlights the delivered recommendations and ratings for Immunomedics Inc. and Cytokinetics Incorporated.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
Immunomedics Inc.’s consensus target price is $28, while its potential upside is 69.29%. Competitively the consensus target price of Cytokinetics Incorporated is $18, which is potential 38.78% upside. The data provided earlier shows that Immunomedics Inc. appears more favorable than Cytokinetics Incorporated, based on analyst opinion.
Institutional & Insider Ownership
Institutional investors held 95.3% of Immunomedics Inc. shares and 70.9% of Cytokinetics Incorporated shares. Insiders held 7.19% of Immunomedics Inc. shares. Comparatively, 1% are Cytokinetics Incorporated’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year Immunomedics Inc. has weaker performance than Cytokinetics Incorporated
Immunomedics Inc. beats on 5 of the 8 factors Cytokinetics Incorporated.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.